Centre de Recherche en Cancérologie de Lyon, Inserm U1052, CNRS UMR 5286, Université de Lyon, Centre Léon Bérard, Lyon, France; Equipe Labellisée la Ligue Contre le Cancer, Lyon, France.
Centre de Recherche en Cancérologie de Lyon, Inserm U1052, CNRS UMR 5286, Université de Lyon, Centre Léon Bérard, Lyon, France; Equipe Labellisée la Ligue Contre le Cancer, Lyon, France.
Trends Pharmacol Sci. 2024 Apr;45(4):287-289. doi: 10.1016/j.tips.2024.01.002. Epub 2024 Jan 20.
B cell leukemia/lymphoma 2 (BCL2) homology domain 3 (BH3) mimetics were reported to selectively kill senescent cells and improve age-related diseases. Defining why these cells show increased sensitivity to these molecules will help to identify new pharmacological compounds with senolytic activity. Here, we discuss how recent research findings provide new clues to understand this vulnerability.
B 细胞白血病/淋巴瘤 2（BCL2）同源结构域 3（BH3）模拟物据报道可选择性地杀死衰老细胞并改善与年龄相关的疾病。确定这些细胞为何对这些分子表现出更高的敏感性将有助于鉴定具有衰老细胞溶解活性的新药理化合物。在这里，我们讨论了最近的研究结果如何为理解这种脆弱性提供新的线索。
